FDA Okays Purdue's Newer OxyContin; Payors And Physicians Chew On Drug's Benefit
This article was originally published in The Pink Sheet Daily
Executive Summary
Purdue's reformulated OxyContin could face generics in 2013 unless FDA withdraws the initial NDA because of safety concerns.